Efficient non-viral transduction and culture of erythroid cells
CA 2260332 A1 · Owner: Bell, David · Inventors: Bell, David; Matthews, Kathryn; Mueller, Susan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention involves 1) efficient non-viral gene transfer into human erythroid progenitors cells and 2) use of a constitutively active human EpoR gene to, prolong the lifespan of progenitor cells. CD34' cells enriched from umbilical cord blood, LDMNC are cultured er vivo at a low density in the absence of supportive stroma for 7 to, days in a serum-free defined culture medium with the addition of IL-3 SCF and , EPO. At this time, cells expand < 70 fold and hematopoietic progenitors are present at a, frequency of 25 BFU-E, 28 CFU-E and 10 CFU-GM per 1 x 10 5 cells as detected by, methylceliulose colony forming assay. Approximately 2% are CD34~ while 40% are GIyA~. …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 25, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 25, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 25, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.